Aveanna Healthcare Holdings, Inc.

AVAH

Nasdaq; healthcare; SIC 8082, Services-Home Health Care Services; CIK 0001832332

C

middle fifth of 369 graded peers in healthcare

rank 198 of 369; percentile 53.5; sampling error 2.5 points; lower is stronger


A B C D E

C, the tortoise




Scoreboard	
Profitability	C percentile 44.3
Solvency	C percentile 56.1
Growth and financing	C percentile 47.0
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $2.0B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	10 of 14
Graded from	filings received through Mar 19, 2026 239 days before the rescan; latest periodic filing 10-Q received Nov 12, 2026
Last close	$12.22 2026-11-12; market equity $2.7B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 19, 2026

Aveanna is a Delaware corporation and was incorporated on November 30, 2016, originally under the name BCPE Oasis Holdings Inc. Aveanna commenced operations in March 2017 in connection with the transformative merger of Epic Health Services Inc. and Pediatric Services of America, Inc. in March 2017 under the name BCPE Eagle Holdings Inc. On May 26, 2017, we changed our name to Aveanna Healthcare Holdings Inc. and commenced trading on the Nasdaq Stock Market on April 29, 2021. Our principal executive offices are located at 400 Interstate North Parkway SE, Suite 1600, Atlanta, Georgia and our phone number is (770) 441-1580. We maintain a website at www.aveanna.com.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 44.3						
Gross profitability	40.3%	32.3%		33.0	365	2026-01-03
Return on invested capital	not computable	9.3%				


Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

pretax income must exceed the validity floor and imply a 0%-100% tax rate

Accruals ratio	5.4%	(6.6%)	88.7	800	2026-01-03
Gross margin stability, five years	0.8 pts	2.8 pts	11.2	242	2026-01-03
Solvency, sleeve percentile 56.1					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	(0.46)	(0.35)	38.9	744	2026-01-03
Net debt to EBITDA	4.16x	1.82x	77.0	75	2026-01-03
Interest coverage	1.83x	(4.51x)	24.7	78	2026-01-03
Current ratio	1.32x	2.95x	83.6	826	2026-01-03
Growth and financing, sleeve percentile 47.0					
Revenue growth, three-year compound	10.8%	10.1%	48.9	412	2026-01-03
Free cash flow growth, three-year compound	not computable	11.0%			
four consecutive annual FCF observations are required; found 1					
Reinvestment rate	not computable	37.1%			
a prior annual working-capital observation is required					
Asset growth, three years	5.5%	2.2%	39.7	694	2026-01-03
Net share issuance, one year	11.5%	2.5%	52.4	627	2026-03-13

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
193	Zai Lab Ltd. (ZLAB)	52.2	C	
194	Perrigo Co. plc (PRGO)	52.4	C	
195	Cabaletta Bio, Inc. (CABA)	52.7	C	dilution
196	Nexgel, Inc. (NXGL)	53.1	C	late filer
197	Nexgel, Inc. (NXGLW)	53.1	C	late filer
198	Aveanna Healthcare Holdings, Inc. (AVAH)	53.5	C	
199	Universal Health Services Inc. (UHS)	53.8	C	
200	Sotera Health Co. (SHC)	54.1	C	
201	Emergent BioSolutions Inc. (EBS)	54.3	C	
202	Roivant Sciences Ltd. (ROIV)	54.6	C	fortress balance sheet
203	Abbott Laboratories (ABT)	54.9	C	

What the price implies

at the 2026-11-12 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	37.1%	(1.9%)	73
Distance from 52-week high	(14.9%)	(30.8%)	66
EBIT to enterprise value	6.8%	(1.9%)	86
Free cash flow yield	(1.0%)	(1.0%)	50
Book value to price	0.13	0.28	29

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Sales to price	0.91	0.29	80
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	0.15	(0.19)	73

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 7 of 9, period end 2026-01-03	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$197.8M
Operating cash flow, four quarters	$207.2M
Months of runway	not finite
Days since last periodic filing	1 (10-Q received Nov 12, 2026)
Median daily dollar volume, 63 sessions	$31.0M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$810.5M	2026-01-03	2026-03-19	10-K	26-115851
2	assets	us-gaap:Assets	$2.0B	2026-01-03	2026-03-19	10-K	26-115851
3	operating income	us-gaap:OperatingIncomeLoss	$256.5M	2026-01-03	2026-03-19	10-K	26-115851
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$106.9M	2026-01-03	2026-03-19	10-K	26-115851
5	income tax	us-gaap:IncomeTaxExpenseBenefit	-$118.1M	2026-01-03	2026-03-19	10-K	26-115851
6	total debt	us-gaap:LongTermDebt	$1.3B	2026-01-03	2026-03-19	10-K	26-115851
7	book equity	us-gaap:StockholdersEquity	$194.5M	2026-01-03	2026-03-19	10-K	26-115851
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$193.3M	2026-01-03	2026-03-19	10-K	26-115851
9	total debt	us-gaap:LongTermDebt	$1.3B	2024-12-28	2026-03-19	10-K	26-115851
10	book equity	us-gaap:StockholdersEquity	-$123.6M	2024-12-28	2026-03-19	10-K	26-115851
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$84.3M	2024-12-28	2026-03-19	10-K	26-115851
12	net income	us-gaap:NetIncomeLoss	$225.0M	2026-01-03	2026-03-19	10-K	26-115851
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$125.9M	2026-01-03	2026-03-19	10-K	26-115851
14	assets	us-gaap:Assets	$1.7B	2024-12-28	2026-03-19	10-K	26-115851
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.4B	2026-01-03	2026-03-19	10-K	26-115851
16	gross profit	us-gaap:GrossProfit	$635.5M	2024-12-28	2026-03-19	10-K	26-115851
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.0B	2024-12-28	2026-03-19	10-K	26-115851
18	gross profit	us-gaap:GrossProfit	$595.4M	2023-12-30	2025-03-13	10-K	25-038504
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.9B	2023-12-30	2025-03-13	10-K	25-038504
20	gross profit	us-gaap:GrossProfit	$553.2M	2022-12-31	2024-03-14	10-K	24-031321
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.8B	2022-12-31	2024-03-14	10-K	24-031321
22	gross profit	us-gaap:GrossProfit	$542.4M	2022-01-01	2023-03-16	10-K	23-008309
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.7B	2022-01-01	2023-03-16	10-K	23-008309
24	current assets	us-gaap:AssetsCurrent	$560.2M	2026-01-03	2026-03-19	10-K	26-115851
25	current liabilities	us-gaap:LiabilitiesCurrent	$424.5M	2026-01-03	2026-03-19	10-K	26-115851
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.2B	2026-01-03	2026-03-19	10-K	26-115851
27	liabilities	us-gaap:Liabilities	$1.8B	2026-01-03	2026-03-19	10-K	26-115851

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

28	depreciation amortization	us-gaap:Depreciation	$9.8M	2026-01-03	2026-03-19	10-K	26-115851
29	interest expense	us-gaap:InterestExpense	$140.1M	2026-01-03	2026-03-19	10-K	26-115851
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$15.9M	2022-01-01	2022-03-28	10-K	22-004799
31	depreciation amortization	us-gaap:Depreciation	$15.3M	2022-01-01	2023-03-16	10-K	23-008309
32	operating income	us-gaap:OperatingIncomeLoss	-$36.1M	2022-01-01	2023-03-16	10-K	23-008309
33	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$113.6M	2022-01-01	2023-03-16	10-K	23-008309
34	income tax	us-gaap:IncomeTaxExpenseBenefit	$3.5M	2022-01-01	2023-03-16	10-K	23-008309
35	current assets	us-gaap:AssetsCurrent	$279.2M	2022-01-01	2023-03-16	10-K	23-008309
36	current liabilities	us-gaap:LiabilitiesCurrent	$344.8M	2022-01-01	2023-03-16	10-K	23-008309
37	assets	us-gaap:Assets	$1.6B	2023-12-30	2025-03-13	10-K	25-038504
38	assets	us-gaap:Assets	$1.7B	2022-12-31	2024-03-14	10-K	24-031321
39	shares outstanding	dei:EntityCommonStockSharesOutstanding	217,510,046	2026-03-13	2026-03-19	10-K	26-115851
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	195,093,866	2025-03-07	2025-03-13	10-K	25-038504

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.